Cash Flow Statement (Annual)

HALO / Halozyme Therapeutics, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss -58,361 -53,242 -19,770 -53,552 -83,479 -68,375 -32,231 -103,023 62,971
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Share Based Compensation 4,526 4,866 5,570 8,349 9,538 15,274 20,838 25,585 30,670
    Depreciation Depletion And Amortization 1,444 1,508 1,096 1,079 1,227 1,762 1,677 2,410 2,200
    Amortization Of Financing Costs - - 0 9 156 2,025 1,243 2,896 1,761
    Paid In Kind Interest - - - - - 0 879 13,184 0
    Accretion Amortization Of Discounts And Premiums Investments - - 0 0 -1,116 -1,457 -879 -552 303
    Gain Loss On Sale Of Property Plant Equipment -3 -14 2 -7 0 -233 -8 -8 -46
    Increase Decrease In Deferred Revenue 11,034 -2,389 -17,210 2,962 9,297 1,490 -1,411 701 22,759
    Recognition Of Deferred Revenue - - - - - 5,554 5,789 9,304 6,512
    Straight Line Rent - - - - - - 276 370 185
    Other Operating Activities Cash Flow Statement - - - - - - 0 0 -16
    Increase Decrease In Operating Capital
      Increase Decrease In Accounts Receivable -3,021 -1,916 -66 13,441 -6,606 52 23,261 -16,730 6,453
      Increase Decrease In Inventories 718 -966 374 2,103 3,499 236 3,083 5,134 -9,477
      Increase Decrease In Prepaid Deferred Expense And Other Assets -1,017 2,147 4,611 4,421 -1,959 265 15,774 -5,626 -2,035
      Increase Decrease In Accounts Payable And Accrued Liabilities -2,000 3,437 712 -3,263 7,889 -816 13,866 -244 15,629
      Net Cash Provided By Used In Operating Activities Continuing Operations - - - - - - -37,083 -50,383 134,053
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Available For Sale Securities - - 0 0 48,947 88,884 71,482 155,412 398,187
  Proceeds From Sale Of Available For Sale Securities - - 0 0 3,375 57,301 79,730 81,783 235,805
  Payments To Acquire Property Plant And Equipment 1,461 647 829 1,413 2,298 1,368 2,360 3,137 1,350
  Net Cash Provided By Used In Investing Activities Continuing Operations - - - - - - 5,888 -76,766 -163,732
Net Cash Provided By Used In Financing Activities
  Proceeds From Issuance Of Common Stock 38,174 59,965 0 81,477 0 107,713 0 0 134,874
  Proceeds From Debt Net Of Issuance Costs - 0 0 29,661 19,985 0 0 203,006 0
  Repayments Of Secured Debt - - - - - 0 0 54,250 15,995
  Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options - - - - 5,079 6,788 13,098 1,865 12,776
  Net Cash Provided By Used In Financing Activities Continuing Operations - - - - - - 13,098 150,621 131,655
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect - - - - - - -18,097 23,472 101,976
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - - 169,240

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related News Stories

Stocks To Watch: Spotlight On Banks, Google Hardware And IPOs

2018-10-06 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (320-4)

Top Analyst Upgrades and Downgrades: Aetna, Analog Devices, Lowe’s, Merck, Pfizer, Plug Power, Qualcomm, Target and More

2018-08-23 247wallst
Stocks were indicated to open lower on Thursday morning, though the S&P 500 hit an all-time high earlier in the week. Earnings season is all but over now and was quite strong, with more than 70% of the companies exceeding expectations. Despite the gains in the market, 2018 has been choppy, and investors have seen less reward in buying every dip than they had been used to in recent years. Many investors also are trying to decide how they want their investments positioned ahead of the midterm elections and given international trade concerns. (44-1)

A Glimpse into the Pancreatic Cancer Pipeline

2018-08-23 biospace
The passing of singing great Aretha Franklin has focused attention on pancreatic cancer. Franklin, 76, succumbed to a neuroendocrine tumor of the pancreas. According to the National Cancer Institute (NCI), pancreatic cancer is relatively rare, with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases. But each year, 44,330 Americans die from the disease, or about 7. (0-1)

Halozyme: A Look At The Q2 2018 Earnings

2018-08-19 seekingalpha
Halozyme Therapeutics (NASDAQ:HALO) is a robust grower that is operating near its growth inflection. Most investment risks are now significantly deleveraged due to the increasing sales from the approved molecules. Despite that that the partnered products in commercialization are delivering meaningful sales, there are substantial unlocked values in the developing pipeline. In the past 52-week, the stock traded up by $4.

Halozyme Therapeutics (HALO) Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 zacks
Halozyme Therapeutics (HALO - Free Report) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. (2-0)

CUSIP: 40637H109